Regent Pacific Group Limited (HKG:0575)
0.9900
-0.0200 (-1.98%)
At close: Feb 13, 2026
Regent Pacific Group Revenue
Regent Pacific Group had revenue of $237.00K USD in the half year ending June 30, 2025, a decrease of -16.25%. This brings the company's revenue in the last twelve months to $833.00K, up 535.88% year-over-year. In the year 2024, Regent Pacific Group had annual revenue of $719.00K with 147.08% growth.
Revenue (ttm)
$833.00K
Revenue Growth
+535.88%
P/S Ratio
44.18
Revenue / Employee
$49.00K
Employees
17
Market Cap
288.90M HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 719.00K | 428.00K | 147.08% |
| Dec 31, 2023 | 291.00K | 177.00K | 155.26% |
| Dec 31, 2022 | 114.00K | -3.14M | -96.50% |
| Dec 31, 2021 | 3.25M | 1.58M | 94.85% |
| Dec 31, 2020 | 1.67M | 1.51M | 918.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 2.20B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.09B |
| Kontafarma China Holdings | 891.73M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| PuraPharm Corporation | 346.76M |
| Tianda Pharmaceuticals | 310.50M |
| Fusen Pharmaceutical Company | 264.08M |
| Pak Fah Yeow International | 199.55M |